Literature DB >> 30030040

Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review.

Kirbee Johnston, Lindsey Alley, Kevin Novak, Sarah Haverly, Adriane Irwin, Daniel Hartung.   

Abstract

OBJECTIVE: While literature on pharmacists' engagement with prescription drug monitoring programs (PDMPs) is growing, no formal synthesis of findings has been conducted to provide overarching recommendations for research or practice. The objective of this study was to identify and synthesize findings from current literature on community pharmacists' attitudes toward, knowledge of, and registration and utilization behaviors regarding PDMPs. DATA SOURCES: Electronic databases (MEDLINE, PsychINFO, Cochrane Database of Systematic Reviews, Google Scholar, and the Brandeis University PDMP Center of Excellence) and reference lists from relevant manuscripts were searched for relevant English-language manuscripts. Key words used in searches included pharmacist, prescription drug monitoring program, opioid safety, attitudes, knowledge, and utilization. STUDY SELECTION: Papers were included from January 1, 2008 up to October 6, 2017. Three authors independently screened articles for full text review; 2 authors independently conducted full text review for final study selection. Discrepancies were resolved through consensus. DATA EXTRACTION: Data were extracted to an evidence table, coded by topic category, and checked for accuracy.
RESULTS: Fifteen manuscripts met inclusion criteria. The studies varied greatly in methodological approach. In general, pharmacists' attitudes and knowledge of PDMPs positively influenced likelihood to register and use their state's program. Targeted training had a substantial impact on knowledge, registration, and utilization.
CONCLUSION: Pharmacist-targeted PDMPs and opioid safety training is highly recommended to increase knowledge of and insight into behavioral change.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2018        PMID: 30030040     DOI: 10.1016/j.japh.2018.06.003

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  6 in total

1.  "Nobody Knows How You're Supposed to Interpret it:" End-user Perspectives on Prescription Drug Monitoring Program in Massachusetts.

Authors:  Mina Hong; Sarah Seymour; Thomas J Stopka; Lane Bandanza; Erin Crocker; Allison Morgan; Leo Beletsky
Journal:  J Addict Med       Date:  2022 May-Jun 01       Impact factor: 4.647

2.  Advances in prescription drug monitoring program research: a literature synthesis (June 2018 to December 2019).

Authors:  Chris Delcher; Nathan Pauly; Patience Moyo
Journal:  Curr Opin Psychiatry       Date:  2020-07       Impact factor: 4.787

3.  Pharmacist Services in the Opioid Crisis: Current Practices and Scope in the United States.

Authors:  Tanvee Thakur; Meredith Frey; Betty Chewning
Journal:  Pharmacy (Basel)       Date:  2019-06-13

4.  Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.

Authors:  Paxton Bach; Daniel Hartung
Journal:  Addict Sci Clin Pract       Date:  2019-09-02

5.  Pharmacists' perceptions on real-time prescription monitoring (RTPM) systems - a cross-sectional survey.

Authors:  Ziyue Zhang; Lin Guo; Ran Si; Leanne Chalmers; Patricia Filippin; Jane Carpenter; Petra Czarniak
Journal:  Explor Res Clin Soc Pharm       Date:  2022-03-02

6.  Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose.

Authors:  Elizabeth Skoy; Oliver Frenzel; Heidi Eukel; Emily Lothspeich; Jayme Steig; Mark Strand; Amy Werremeyer
Journal:  Prev Chronic Dis       Date:  2022-07-14       Impact factor: 4.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.